Pharming Group N.V. (AMS:PHARM)
Netherlands · Delayed Price · Currency is EUR 1.109
-0.025 (-2.21%)
Nov 4, 2026, 5:35 PM CET
Pharming Group Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 386.75 | 376.13 | 297.2 | 245.32 | 205.62 | 198.87 |
Revenue Growth | 6.76% | 26.56% | 21.15% | 19.30% | 3.40% | -6.27% |
Gross Profit Gross Profit Growth | 339.06 | 330.63 | 261.8 | 220.1 | 188.06 | 177.73 |
Operating Income Operating Income Growth | 49.42 | 32.76 | -3.59 | -21.75 | 10.37 | 24 |
Net Income Net Income Growth | 24.18 | 2.85 | -11.84 | -10.55 | 13.67 | 16 |
Earnings Per Share EPS Growth | 0.03 | 0.00 | -0.02 | -0.02 | 0.02 | 0.02 |
EPS Growth | 13053.67% | - | - | - | -17.39% | -58.18% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Ruconest® Ruconest® Growth | 311.22 | 317.92 | 252.24 | 227.13 | 205.62 | 198.87 |
Joenja® Joenja® Growth | 75.51 | 58.21 | 44.96 | 18.18 | - | - |
Total Total Growth | 386.73 | 376.13 | 297.2 | 245.32 | 205.62 | 198.87 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 189.56 | 179.1 | 167.89 | 213.42 | 207.34 | 191.92 |
Total Debt Total Debt Growth | 114.51 | 115.78 | 112.31 | 171.55 | 166.69 | 161.76 |
Net Cash (Debt) Net Cash Growth | 75.05 | 63.33 | 55.58 | 41.88 | 40.65 | 30.16 |
Net Cash Growth | 112.92% | 13.94% | 32.72% | 3.03% | 34.76% | -30.18% |
Net Cash Per Share Net Cash Per Share Growth | 0.09 | 0.08 | 0.08 | 0.06 | 0.06 | 0.04 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 35.37 | 54.71 | -1.8 | -17.3 | 22.46 | 37.84 |
Capital Expenditures CapEx Growth | -0.87 | -0.75 | -0.79 | -1.44 | -1.38 | -10.74 |
Free Cash Flow Free Cash Flow Growth | 34.5 | 53.96 | -2.59 | -18.74 | 21.08 | 27.1 |
Free Cash Flow Growth | -34.56% | - | - | - | -22.21% | -65.68% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 87.67% | 87.90% | 88.09% | 89.72% | 91.46% | 89.37% |
Operating Margin | 12.78% | 8.71% | -1.21% | -8.87% | 5.04% | 12.07% |
Pretax Margin | 8.88% | 3.42% | -2.86% | -4.90% | 7.29% | 11.60% |
Profit Margin | 6.25% | 0.76% | -3.98% | -4.30% | 6.65% | 8.04% |
FCF Margin | 8.92% | 14.35% | -0.87% | -7.64% | 10.25% | 13.63% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 43.90 | 402.37 | - | - | 55.27 | 35.75 |
Forward PE | 33.65 | 60.69 | 60.69 | 170.09 | 28.96 | 16.47 |
P/FCF Ratio | 26.58 | 21.26 | - | - | 35.85 | 21.10 |
PS Ratio | 2.37 | 3.05 | 2.19 | 3.11 | 3.68 | 2.88 |